ML-DS typically develops by the age of 4 years [55] and is always preceded by the prenatal development of somatic mutations in the hematopoietic transcription factor gene GATA1 that result in transient leukemia with or without clinical manifestations (transient abnormal myelopoiesis, TAM, or “silent TAM”, respectively) [56]. The gene discussed is GATA1; the disease is Dravet syndrome.